TLSI

TriSalus Life Sciences, Inc.

5.75 USD
+0.03 (+0.52%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TriSalus Life Sciences, Inc. stock is down -42.33% since 30 days ago. The next earnings date is Aug 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.